Competing in a Crowded ADC Landscape: What Does True Clinical Differentiation Look Like in Today’s ADC Market?

• How can we improve toxicity profiles and delivery better than Enhertu?
• What and how are leaders achieving efficacy beyond a monospecific with a BsAb and BsADCs
• Leveraging synergy between biology of targets and binding events to improve ADC performance

Speakers:

Daeseung Lee

CEO

Portrai

Michael Chisamore

Executive Director Scientist), Oncology Clinical Research, Early Development

Merck

Jing Li

Founder & Chief Executive Officer

VelaVigo

JayJay Lee

Chief Executive Officer

FatiAbGen